• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

    1/11/23 1:00:00 PM ET
    $AEZS
    $AIM
    $AMAO
    $AREC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AEZS alert in real time by email

    - Live video webcast presentations with participating companies -

    FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. As part of the virtual event, participating companies will provide a corporate presentation.

    The schedule for the event is as follows:

    Tuesday, January 17, 2023

    • 9:00 AM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - WEBCAST
    • 10:00 AM ET: Xenetic Biosciences, Inc. (NASDAQ:XBIO) - WEBCAST
    • 11:00 AM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - WEBCAST
    • 1:00 PM ET: Vallon Pharmaceuticals, Inc. (NASDAQ:VLON)/GRI Bio (Private) - WEBCAST
    • 2:00 PM ET: Novan, Inc. (NASDAQ:NOVN) - WEBCAST
    • 3:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - WEBCAST
    • 4:00 PM ET: American Resources Corporation (NASDAQ:AREC) - WEBCAST

    Wednesday, January 18, 2023

    • 10:00 AM ET: CNS Pharmaceuticals Inc. (NASDAQ:CNSP) - WEBCAST
    • 11:00 AM ET:AIM ImmunoTech Inc. (NYSE:AIM) - WEBCAST
    • 1:00 PM ET: Panavance Therapeutics Inc. (Private) - WEBCAST
    • 2:00 PM ET: ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) -WEBCAST
    • 3:00 PM ET: Ceapro, Inc. (TSXV:CZO, OTCQX:CRPOF) - WEBCAST
    • 4:00 PM ET: iTolerance, Inc. (Private) - WEBCAST

    Thursday, January 19, 2023

    • 10:00 AM ET: Adolore Biotherapeutics, Inc. (Private) - WEBCAST
    • 11:00 AM ET: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) - WEBCAST
    • 1:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - WEBCAST
    • 2:00 PM ET: American Acquisition Opportunity Inc. (NASDAQ:AMAO) - WEBCAST
    • 3:00 PM ET: Aeterna Zentaris Inc. (NASDAQ:AEZS, TSX:AEZS) - WEBCAST
    • 4:00 PM ET: SurgePays, Inc. (NASDAQ:SURG) - WEBCAST

    About JTC Team

    JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    [email protected]

    SOURCE: JTC Team, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/734876/JTC-Team-to-Host-the-Virtual-Investor-2023-Companies-to-Watch-Event-on-January-17th-18th-and-19th

    Get the next $AEZS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEZS
    $AIM
    $AMAO
    $AREC

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    American Resources Corporation
    $AREC
    11/26/2025$7.00Buy
    Maxim Group
    American Resources Corporation
    $AREC
    10/20/2025Outperform
    William Blair
    American Resources Corporation
    $AREC
    9/15/2025$6.00Buy
    D. Boral Capital
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AEZS
    $AIM
    $AMAO
    $AREC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director May David Allen bought $61,647 worth of Shares of Common Stock (38,422 units at $1.60), increasing direct ownership by 32% to 158,116 units (SEC Form 4)

    4 - SurgePays, Inc. (0001392694) (Issuer)

    12/11/25 9:37:54 PM ET
    $SURG
    Advertising
    Consumer Discretionary

    $AEZS
    $AIM
    $AMAO
    $AREC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cox Kevin Brian

    4 - SurgePays, Inc. (0001392694) (Issuer)

    4/7/26 3:44:40 PM ET
    $SURG
    Advertising
    Consumer Discretionary

    CEO & President Equels Thomas K converted options into 25,000 shares, increasing direct ownership by 64% to 63,922 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/16/26 5:30:41 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chemerow David I. converted options into 25,000 shares, increasing direct ownership by 727% to 28,441 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/16/26 5:30:12 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    4/7/26 4:15:24 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Inc. filed SEC Form 8-K: Other Events

    8-K - PALISADE BIO, INC. (0001357459) (Filer)

    4/2/26 8:34:41 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-K filed by SurgePays Inc.

    NT 10-K - SurgePays, Inc. (0001392694) (Filer)

    3/31/26 4:49:23 PM ET
    $SURG
    Advertising
    Consumer Discretionary

    $AEZS
    $AIM
    $AMAO
    $AREC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

    Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Needham & Co. 25th Annual Healthcare Conference, being held in a virtual format April 14–17, 2026. The Company's virtual presentation is scheduled for Thursday, April 16, 2026, f

    4/8/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

    ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has granted a meeting with the deciding official to be conducted

    4/7/26 8:50:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

    Access the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. In this segment, Mr. Klemp highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. Annamycin was specifically designed to avoid cardiac damage, and has demonstrated this advantage across preclinical and clinical studies. This non-cardiotoxic profile could expand treatment opt

    4/7/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Palisade Bio with a new price target

    H.C. Wainwright initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    3/26/26 8:49:56 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Financials

    Live finance-specific insights

    View All

    SurgePays to Host Fourth Quarter and Full Year 2025 Earnings Conference Call

    BARTLETT, Tenn., March 31, 2026 (GLOBE NEWSWIRE) -- SurgePays, Inc. (NASDAQ:SURG)("SurgePays" or the "Company"), a wireless and fintech point of sale company connecting subprime and underserved consumers to essential mobile and financial services, today announced that it plans to host a conference call and report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, April 14, 2026. Event: SurgePays Fourth Quarter and Full Year 2025 Financial Results Conference CallDate: Tuesday, April 14, 2026Time: 5:00 p.m. E.T.Dial-in Number: 1-888-506-0062Access Code: 395490Webcast: https://ir.surgepays.com/company-events The webcast replay will remain availab

    3/31/26 4:35:00 PM ET
    $SURG
    Advertising
    Consumer Discretionary

    Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

    PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement, with a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and 40% of patients achieving endoscopic remissionPharmacokinetic and pharmacodynamic data from ileal tissue and plasma support once-daily oral dosing for Crohn's disease showing IC90 coverage, with correlation to accepted inflammatory biomarkers Data support expansion into broader luminal CD, an indication that has regulatory clarity, more than doubles the total addressable patient population, and has no a

    3/30/26 4:01:00 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care